Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

RET

7 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology

Utility of RNA Sequencing and Immunohistochemistry for NTRK Fusion in Thyroid Carcinoma

Toda S, Kasajima R, Okubo Y, et al.

Anticancer research

This study evaluated the utility of RNA sequencing and immunohistochemistry (IHC) for detecting NTRK fusions in thyroid carcinoma, particularly those potentially missed by gene panel testing. Two patient groups were analyzed: advanced thyroid cancer cases undergoing panel testing and surgical papillary thyroid carcinoma cases screened by IHC. Results indicated that a gene panel test missed one SQSTM1-NTRK3 fusion, while pan-TRK IHC showed variable sensitivity depending on the fusion type. The study concludes that active screening for NTRK fusions is desirable, especially in patients without MAPK pathway abnormalities or with positive pan-TRK staining.

Clinical

RET-driven osteoprotegerin expression links medullary thyroid cancer to osteoblastic bone metastases

Bagheri-Yarmand R, Pagnotti GM, Kidd JL, et al.

Cell reports. Medicine

This study investigates the mechanisms underlying osteoblastic bone metastases in medullary thyroid cancer (MTC), which are associated with high mortality. Researchers found that activated RET protein in MTC cells stimulates the expression of osteoprotegerin (OPG), an inhibitor of bone resorption. This process leads to reduced osteoclast differentiation and promotes an osteoblastic phenotype. RET inhibition was shown to reduce tumor burden and bone lesions in mice. Furthermore, elevated circulating OPG levels in MTC patients with bone metastases correlate with poorer overall survival, suggesting OPG as a potential biomarker.

Clinical

Selpercatinib Improves EFS in RET Fusion-Positive NSCLC

Cancer discovery

Results from the LIBRETTO-432 study indicate that adjuvant selpercatinib substantially improves event-free survival in patients with early-stage RET fusion-positive non-small cell lung cancer (NSCLC). This finding establishes selpercatinib as a new standard of care for this rare disease. Nevertheless, challenges persist regarding patient identification and access to RET fusion screening.

Molecular biology

Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing

Masago K, Seto K, Sasaki E, et al.

Genes, chromosomes & cancer

This study investigated oncogenic fusions in 11 unclassified pulmonary spindle cell tumors, aggressive neoplasms with limited treatment options. Using anchored multiplex PCR-based targeted RNA sequencing, researchers identified ALK gene fusions in two patients (18.2%), specifically PPFIBP1::ALK and SYCL3::ALK. Both tumors also exhibited positive ALK immunohistochemical staining, despite showing morphological heterogeneity. These findings expand the molecular spectrum of these rare tumors and highlight the importance of detecting ALK fusions, including those with uncommon partners.

Clinical

Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer

Wu YL, Hochmair M, Yang Y, et al.

The New England journal of medicine

This phase 3 study, LIBRETTO-432, investigated the efficacy and safety of adjuvant selpercatinib in patients with early-stage (IB, II, or IIIA) RET fusion-positive non-small-cell lung cancer (NSCLC) after definitive therapy. Patients were randomized to receive selpercatinib or placebo for up to three years. The primary endpoint was event-free survival (EFS) in patients with stage II or IIIA disease. Results demonstrated a significant improvement in 2-year EFS with selpercatinib (92% vs 61% for stage II/IIIA, HR=0.17), with a similar trend across all stage IB-IIIA patients (94% vs 70%, HR=0.16). The safety profile was manageable, with elevated transaminases being the most common adverse events.

Clinical

First-line versus second-line use of selpercatinib in treatment of RET fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis

Wang K, Liu W

Clinical & translational oncology

This study evaluated the cost-effectiveness of selpercatinib as a first-line or second-line treatment compared to chemotherapy alone for advanced RET fusion-positive non-small cell lung cancer (NSCLC) from the perspective of US payers. A partitioned survival model was employed to compare clinical outcomes and costs. The findings indicated that selpercatinib, whether used first-line or second-line, was not deemed cost-effective at the current willingness-to-pay threshold of $150,000 per quality-adjusted life-year (QALY). To achieve cost-effectiveness, a substantial price reduction for selpercatinib (approximately 70-77%) would be required. The study concludes that further real-world evidence is needed to inform clinical and health policy decisions.

Clinical · Molecular biology

MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies

Aldea M, Lenahan SM, Locquet MA, et al.

Annals of oncology

Homozygous MTAP loss is frequently observed in oncogene-driven non-small-cell lung cancers (NSCLC), particularly in EGFR, ALK, and RET altered subtypes. While this loss did not significantly impact the response to first-line targeted therapies, it creates a selective vulnerability to PRMT5 inhibitors. Preclinical studies demonstrated that the PRMT5 inhibitor BMS-986504 is active in MTAP-deleted NSCLC models and can enhance the efficacy of existing targeted therapies. These findings suggest a novel combined therapeutic strategy for NSCLC patients with MTAP loss.